Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Jasper Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Jasper Therapeutics, Inc.

JSPR JSPRW

Jasper Therapeutics, Inc.

About Jasper Therapeutics, Inc.

Jasper Therapeutics is a biotech company focused on developing therapies for mast cell-driven diseases such as chronic urticarias, asthma, and other inflammatory conditions. Its lead candidate, briquilimab, is a monoclonal antibody targeting the c-Kit receptor to deplete mast cells and support stem cell transplantation. The company advances clinical programs, collaborates with industry and academia, and seeks regulatory approval to bring innovative immune modulation treatments to patients worldwide.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Jasper Therapeutics, Inc.

1
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports Reduced Net Loss and Strategic Focus on Briquilimab

Via official filing (AI summary) | 21 days ago | 0 comments

2
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports $75.8 Million Net Loss for Fiscal Year 2025, Focuses on Mast Cell Disease Programs

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports $18.7 Million Net Loss in Q3 2025 Amid Rising R&D Expenses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports $26.7 Million Net Loss and Organizational Restructuring

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports $21.2 Million Net Loss in Q1 2025, Faces Financial Challenges

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports $71.3 Million Net Loss for 2024, Advances Briquilimab in Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Jasper Therapeutics, Inc. Jasper Therapeutics Reports Third Quarter Financial Results, Net Loss of $18.6 Million

Via official filing (AI summary) | over 1 year ago | 0 comments